Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.03
Nov 18 • 3:54 PM ET Dollar change-0.03 Percentage change(-2.83%)
Aftermarket Close
1.03
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
74.50M
Enterprise Value
11.93M
Income
-65.33M
Sales
56.42M
Book/sh
0.41
Cash/sh
2.31
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
229
IPO
Mar 25, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
1.32
P/B
2.53
P/C
0.45
P/FCF
-
EV/EBITDA
-
EV/Sales
0.21
Quick Ratio
1.37
Current Ratio
1.37
Debt/Eq
2.54
LT Debt/Eq
2.19
Option/Short
Yes / Yes
EPS (ttm)
-0.65
EPS next Y
-0.86
EPS next Q
-0.26
EPS this Y
-80.77%
EPS next Y
28.60%
EPS next 5Y
-28.02%
EPS past 3/5Y
33.81% 18.84%
Sales past 3/5Y
56.25% -0.34%
EPS Y/Y TTM
-13.99%
Sales Y/Y TTM
-0.11%
EPS Q/Q
9.72%
Sales Q/Q
-69.19%
Insider Own
3.93%
Insider Trans
0.00%
Inst Own
13.17%
Inst Trans
1.07%
ROA
-21.03%
ROE
-94.56%
ROIC
-49.84%
Gross Margin
66.25%
Oper. Margin
-116.10%
Profit Margin
-115.79%
SMA20
-6.90%
SMA50
-21.90%
SMA200
-64.23%
Trades
Shs Outstand
100.70M
Shs Float
69.48M
52W High
5.45 -81.10%
52W Low
0.88 16.94%
Volatility
10.47% 10.89%
ATR (14)
0.14
RSI (14)
41.90
Beta
3.14
Rel Volume
0.05
Avg Volume
113.01K
Volume
6,025
Perf Week
-25.36%
Perf Month
4.04%
Perf Quarter
-70.32%
Perf Half Y
-71.86%
Perf YTD
-78.72%
Perf Year
-74.94%
Perf 3Y
-64.85%
Perf 5Y
-88.68%
Perf 10Y
-94.25%
Prev Close
1.06
Price
1.03
Change %
-2.83%
Consensus
Hold
Avg. Price Target
$4.75
Implied Upside
+361.2%
Analysts12incl. previous ratings
Rating Distribution6 Buy · 4 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 16, 2026Downgrade
BCS logoBBarclays
Overweight → Underweight$1.30+26.2%
Sep 15, 2026Downgrade
CCitizens
Mkt Outperform → Mkt Perform
May 28, 2026Initiated
BCS logoBBarclays
Overweight$9+773.8%
Feb 17, 2026Resumed
JEF logoJJefferies
Buy$7+579.6%
Mar 17, 2023Initiated
BBryan Garnier
Buy$6+482.5%
May 18, 2022Upgrade
RRobert W. Baird
Neutral → Outperform$10+870.9%
Jan 06, 2022Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$39 → $16+1,453.4%
Nov 30, 2021Initiated
JJMP Securities
Mkt Outperform$20+1,841.7%
Nov 08, 2021Downgrade
WWilliam Blair
Outperform → Mkt Perform
Oct 08, 2021Downgrade
RRobert W. Baird
Outperform → Neutral$39 → $10+870.9%
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.
Co-FounderDr. Andre Choulika Ph.D.
Co-FounderDr. David J. Sourdive Ph.D.
CFO & Chief Business OfficerMr. Arthur Stril
Principal Financial Officer & Principal Accounting OfficerValerie Cros
Chief Technological OfficerMr. Jean Charles Epinat Ph.D.